Repros Therapeutics, Inc. (RPRX) Posts Wider than Expected Q2 Loss of 21c/Share
Tweet
Share
E-mailGet Alerts RPRX Hot Sheet
Price: $59.13 +0.90%
Financial Fact:
Research and development: 3.18M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Research and development: 3.18M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Repros Therapeutics, Inc. (NASDAQ: RPRX) reported Q2 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19).
For earnings history and earnings-related data on Repros Therapeutics, Inc. (RPRX) click here.
For earnings history and earnings-related data on Repros Therapeutics, Inc. (RPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30
- Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
